S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.59 (-2.28%)
BABA   84.14 (-2.76%)
AMD   102.23 (-1.01%)
T   14.72 (+0.34%)
F   12.16 (-1.22%)
MU   68.83 (+1.28%)
CGC   0.72 (-2.89%)
GE   108.95 (+0.15%)
DIS   81.21 (-0.56%)
AMC   8.10 (-0.61%)
PFE   33.92 (-0.06%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.59 (-2.28%)
BABA   84.14 (-2.76%)
AMD   102.23 (-1.01%)
T   14.72 (+0.34%)
F   12.16 (-1.22%)
MU   68.83 (+1.28%)
CGC   0.72 (-2.89%)
GE   108.95 (+0.15%)
DIS   81.21 (-0.56%)
AMC   8.10 (-0.61%)
PFE   33.92 (-0.06%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.59 (-2.28%)
BABA   84.14 (-2.76%)
AMD   102.23 (-1.01%)
T   14.72 (+0.34%)
F   12.16 (-1.22%)
MU   68.83 (+1.28%)
CGC   0.72 (-2.89%)
GE   108.95 (+0.15%)
DIS   81.21 (-0.56%)
AMC   8.10 (-0.61%)
PFE   33.92 (-0.06%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.59 (-2.28%)
BABA   84.14 (-2.76%)
AMD   102.23 (-1.01%)
T   14.72 (+0.34%)
F   12.16 (-1.22%)
MU   68.83 (+1.28%)
CGC   0.72 (-2.89%)
GE   108.95 (+0.15%)
DIS   81.21 (-0.56%)
AMC   8.10 (-0.61%)
PFE   33.92 (-0.06%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
Most-Downgraded StocksMost-Downgraded
NASDAQ:ILMN

Illumina (ILMN) Stock Forecast, Price & News

$135.45
-0.99 (-0.73%)
(As of 10:04 AM ET)
Compare
Today's Range
$134.77
▼
$135.90
50-Day Range
$128.91
▼
$192.44
52-Week Range
$127.37
▼
$248.87
Volume
98,174 shs
Average Volume
1.44 million shs
Market Capitalization
$21.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$222.85
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
63.3% Upside
$222.85 Price Target
Short Interest
Healthy
3.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.44mentions of Illumina in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$178,560 Sold Last Quarter
Proj. Earnings Growth
191.57%
From $0.83 to $2.42 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

66th out of 975 stocks

Analytical Instruments Industry

5th out of 29 stocks

See Top Rated MarketRank™ Stocks Here

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

ILMN Price History

ILMN Stock News Headlines

October 3, 2023 | americanbankingnews.com
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Brokerages
October 1, 2023 | msn.com
Bernstein bullish on Thermo, Revvity, Guardant, PacBio; bearish on Illumina
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
October 1, 2023 | americanbankingnews.com
HSBC Lowers Illumina (NASDAQ:ILMN) Price Target to $171.00
October 1, 2023 | americanbankingnews.com
Illumina (NASDAQ:ILMN) Price Target Cut to $200.00
October 1, 2023 | americanbankingnews.com
Illumina (NASDAQ:ILMN) PT Lowered to $100.00
September 30, 2023 | americanbankingnews.com
Illumina (NASDAQ:ILMN) Receives New Coverage from Analysts at Sanford C. Bernstein
September 30, 2023 | americanbankingnews.com
Equities Analysts Set Expectations for Illumina, Inc.'s Q2 2024 Earnings (NASDAQ:ILMN)
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 29, 2023 | benzinga.com
Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
September 29, 2023 | msn.com
Bernstein Initiates Coverage of Illumina (ILMN) with Underperform Recommendation
September 28, 2023 | prnewswire.com
The Singleton Leads Scotch Whisky to Embrace Chinese Reunion Culture
September 27, 2023 | finance.yahoo.com
Summiting Italy’s Stelvio Pass for Cancer Research
September 21, 2023 | businesswire.com
Illumina Ventures Announces New Partner, Mara Aspinall, Has Joined Its Investment Team
September 20, 2023 | benzinga.com
Looking At Illumina's Recent Unusual Options Activity
September 20, 2023 | finance.yahoo.com
Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
September 18, 2023 | finance.yahoo.com
Yes, It’s Possible: Students Visit Illumina and See Their Potential Careers
September 15, 2023 | finance.yahoo.com
Why Pathogen Surveillance Is Critical During a “Tripledemic”
September 13, 2023 | marketwatch.com
Illumina Inc. stock underperforms Wednesday when compared to competitors despite daily gains
September 13, 2023 | finance.yahoo.com
Insights From Dublin: Fostering Precision Oncology for Better Patient Outcomes
September 13, 2023 | prnewswire.com
Collaboration Between Illumina Inc. and AstraZeneca Promises Groundbreaking Drug Target Discovery Using AI-Based Genomic Analysis Techniques
September 11, 2023 | finance.yahoo.com
UK Stem Students Get Hands-On Lessons in Biodiversity and Genomics
September 11, 2023 | seekingalpha.com
Illumina, Inc. (ILMN) Morgan Stanley 21st Annual Global Healthcare Conference - (Transcript)
September 9, 2023 | finance.yahoo.com
Is the Worst Over for Illumina Stock?
September 8, 2023 | msn.com
Billionaire Activist Investor Carl Icahn Shows Support For Illumina's Newly Appointed CEO
September 7, 2023 | msn.com
Carl Icahn says new Illumina CEO has his 'full support' months after proxy fight
September 6, 2023 | morningstar.com
Illumina Inc ILMN Stock Quote
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
8/09/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
CIK
1110803
Web
www.illumina.com
Phone
(858) 202-4500
Fax
858-202-4766
Employees
10,260
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$222.85
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$100.00
Forecasted Upside/Downside
+63.3%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($26.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
164.39
P/E Growth
7.42
Net Income
$-4,404,000,000.00
Net Margins
-93.86%
Pretax Margin
-89.80%
Return on Equity
1.97%
Return on Assets
1.11%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
1.40
Quick Ratio
1.13

Sales & Book Value

Annual Sales
$4.58 billion
Price / Sales
4.71
Cash Flow
$4.61 per share
Price / Cash Flow
29.58
Book Value
$41.95 per share
Price / Book
3.25

Miscellaneous

Outstanding Shares
158,300,000
Free Float
158,094,000
Market Cap
$21.60 billion
Optionable
Optionable
Beta
1.16

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 52)
    Ph.D., CFO, Chief Strategy & Corp. Devel. Officer
    Comp: $787.3k
  • Ms. Susan H. TousiMs. Susan H. Tousi (Age 54)
    Chief Commercial Officer
    Comp: $790.2k
  • Mr. Charles E. Dadswell Esq. (Age 64)
    Interim CEO & Gen. Counsel
  • Stephanie Campos
    Pres
  • Mr. Kevin Carl Pegels (Age 56)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 51)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 53)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    VP of Investor Relations
  • Ms. Kathryne Gambrell Reeves (Age 54)
    Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

17 analysts have issued 12-month price targets for Illumina's stock. Their ILMN share price forecasts range from $100.00 to $350.00. On average, they anticipate the company's share price to reach $222.85 in the next twelve months. This suggests a possible upside of 63.3% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 at the beginning of 2023. Since then, ILMN stock has decreased by 32.5% and is now trading at $136.44.
View the best growth stocks for 2023 here.

Are investors shorting Illumina?

Illumina saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 5,950,000 shares, an increase of 5.5% from the August 31st total of 5,640,000 shares. Based on an average trading volume of 1,560,000 shares, the short-interest ratio is currently 3.8 days.
View Illumina's Short Interest.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ILMN earnings forecast.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Wednesday, August, 9th. The life sciences company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.30. The life sciences company had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $1.16 billion. Illumina had a positive trailing twelve-month return on equity of 1.97% and a negative net margin of 93.86%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.57 earnings per share.
Read the conference call transcript.

What ETFs hold Illumina's stock?

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of $0.75-$0.90 for the period, compared to the consensus EPS estimate of $1.31. The company issued revenue guidance of $4.63 billion-$4.63 billion, compared to the consensus revenue estimate of $4.91 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $136.44.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $21.60 billion and generates $4.58 billion in revenue each year. The life sciences company earns $-4,404,000,000.00 in net income (profit) each year or ($26.61) on an earnings per share basis.

How many employees does Illumina have?

The company employs 10,260 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -